Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring

Introduction: Chronic antibody-mediated rejection (cAMR) has very few effective therapeutic options. Interleukin-6 is an attractive target because it is involved in inflammation and humoral immunity. Therefore, the use of tocilizumab (anti-IL6 receptor, TCZ) is a potential valuable therapeutic optio...

Descripción completa

Detalles Bibliográficos
Autores principales: Noble, Johan, Giovannini, Diane, Laamech, Reda, Imerzoukene, Farida, Janbon, Bénédicte, Marchesi, Laura, Malvezzi, Paolo, Jouve, Thomas, Rostaing, Lionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739887/
https://www.ncbi.nlm.nih.gov/pubmed/35004757
http://dx.doi.org/10.3389/fmed.2021.790547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739887/
https://www.ncbi.nlm.nih.gov/pubmed/35004757
http://dx.doi.org/10.3389/fmed.2021.790547

Ejemplares similares